Standard Biotools Net Worth
Standard Biotools Net Worth Breakdown | LAB |
Standard Biotools Net Worth Analysis
Standard Biotools' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Standard Biotools' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Standard Biotools' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Standard Biotools' net worth analysis. One common approach is to calculate Standard Biotools' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Standard Biotools' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Standard Biotools' net worth. This approach calculates the present value of Standard Biotools' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Standard Biotools' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Standard Biotools' net worth. This involves comparing Standard Biotools' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Standard Biotools' net worth relative to its peers.
Enterprise Value |
|
To determine if Standard Biotools is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Standard Biotools' net worth research are outlined below:
| Standard Biotools generated a negative expected return over the last 90 days | |
| Standard Biotools may become a speculative penny stock | |
| Standard Biotools has high historical volatility and very poor performance | |
| Standard Biotools has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 106.34 M. Reported Net Loss for the year was (74.66 M) with loss before taxes, overhead, and interest of (1.45 M). | |
| Standard Biotools has about 81.31 M in cash with (43.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Standard Biotools has a poor financial position based on the latest SEC disclosures | |
| Roughly 73.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Bioservo Collaborates with Limb Lab to Expand Accessibility of Carbonhand Across the United States |
Standard Biotools Quarterly Good Will |
|
Standard Biotools uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Standard Biotools. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Standard Biotools' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Follow Standard Biotools' market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 636.56 M.Market Cap |
|
Project Standard Biotools' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.36) | |
| Return On Capital Employed | (0.36) | (0.38) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.46) | (0.48) |
When accessing Standard Biotools' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Standard Biotools' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Standard Biotools' profitability and make more informed investment decisions.
Please note, the presentation of Standard Biotools' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Standard Biotools' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Standard Biotools' management manipulating its earnings.
Evaluate Standard Biotools' management efficiency
Standard Biotools has Return on Asset of (0.1469) % which means that on every $100 spent on assets, it lost $0.1469. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3725) %, meaning that it generated no profit with money invested by stockholders. Standard Biotools' management efficiency ratios could be used to measure how well Standard Biotools manages its routine affairs as well as how well it operates its assets and liabilities. As of November 28, 2024, Return On Tangible Assets is expected to decline to -0.36. In addition to that, Return On Capital Employed is expected to decline to -0.38. At present, Standard Biotools' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 3.4 M, whereas Total Assets are forecasted to decline to about 228.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.06 | 2.16 | |
| Tangible Book Value Per Share | 0.70 | 0.74 | |
| Enterprise Value Over EBITDA | (4.07) | (4.27) | |
| Price Book Value Ratio | 1.07 | 2.08 | |
| Enterprise Value Multiple | (4.07) | (4.27) | |
| Price Fair Value | 1.07 | 2.08 | |
| Enterprise Value | 376.6 M | 274.1 M |
Evaluating the management effectiveness of Standard Biotools allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Standard Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 2.3073 | Revenue 155.9 M | Quarterly Revenue Growth (0.14) | Revenue Per Share 0.558 | Return On Equity (0.37) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Standard Biotools insiders, such as employees or executives, is commonly permitted as long as it does not rely on Standard Biotools' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Standard Biotools insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Standard Biotools time-series forecasting models is one of many Standard Biotools' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Standard Biotools' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Standard Biotools Earnings per Share Projection vs Actual
Standard Biotools Corporate Management
| Jeffrey Black | Chief Officer | Profile | |
| Shane Bowen | Chief Officer | Profile | |
| Mark Spearman | Sr Communications | Profile | |
| Dr Dphil | CoFounder Board | Profile | |
| Peter DeNardo | Investor Relations | Profile | |
| Stephen Linthwaite | Advisor | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. If investors know Standard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Standard Biotools listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.558 | Quarterly Revenue Growth (0.14) | Return On Assets (0.15) | Return On Equity (0.37) |
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Standard Biotools' value and its price as these two are different measures arrived at by different means. Investors typically determine if Standard Biotools is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Standard Biotools' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.